Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

NIRSEVIMAB-ALIP for Immunisation: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 107 adverse event reports in the FDA FAERS database where NIRSEVIMAB-ALIP was used for Immunisation.

Most Reported Side Effects for NIRSEVIMAB-ALIP

Side Effect Reports % Deaths Hosp.
Drug ineffective 173 22.1% 1 127
Respiratory syncytial virus bronchiolitis 135 17.2% 1 72
Bronchiolitis 83 10.6% 0 65
Incorrect dose administered 80 10.2% 0 2
Respiratory syncytial virus infection 76 9.7% 2 54
Pyrexia 54 6.9% 0 29
Cough 45 5.8% 0 25
Respiratory syncytial virus test positive 36 4.6% 1 30
Extra dose administered 30 3.8% 0 0
Product storage error 30 3.8% 0 0
Rash 25 3.2% 0 6
Oxygen therapy 22 2.8% 0 22
Product administered to patient of inappropriate age 20 2.6% 0 0
Respiratory distress 17 2.2% 0 14
Urticaria 17 2.2% 0 4

Other Indications for NIRSEVIMAB-ALIP

Respiratory syncytial virus immunisation (170) Antiviral prophylaxis (137) Prophylaxis (26) Respiratory syncytial virus infection (22) Product used for unknown indication (16)

Other Drugs Used for Immunisation

INFLUENZA VIRUS VACCINE (560) PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (281) COVID-19 VACCINE NOS (269) TOZINAMERAN (207) MEASLES VIRUS STRAIN ENDERS^ ATTENUATED EDMONSTON LIVE ANTIGEN\MUMPS VIRUS STRAIN B LEVEL JERYL LYNN LIVE ANTIGEN\RUBELLA VIRUS STRAIN WISTAR RA 27/3 LIVE ANTIGEN (152) TUBERCULIN PURIFIED PROTEIN DERIVATIVE (148) PNEUMOCOCCAL VACCINE POLYVALENT (140) VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN (123) AD26.COV2.S (113) STREPTOCOCCUS PNEUMONIAE TYPE 1 CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN\STREPTOCOCCUS PNEUMONIAE TYPE 14 CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN\STREPTOCOCCUS PNEUMONIAE TYPE 18C CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN\STREPTOCOCCUS PNEUMONIAE TYPE 19A CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE ANTIGEN\STREPTOCOCCUS PNEUMONIAE TYPE 19F CAPSULAR POLYSACCHARIDE DIPHTHERIA CRM197 PROTEIN CONJUGATE A (111)

Related Pages

NIRSEVIMAB-ALIP Full Profile All Immunisation Drugs NIRSEVIMAB-ALIP Demographics NIRSEVIMAB-ALIP Timeline